PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Shepherd, Frances A.
TI  - State of the Art Treatment for Lung Cancer
DP  - 2013 Aug 01
TA  - MD Conference Express
PG  - 32--33
VI  - 13
IP  - 6
4099  - http://mdc.sagepub.com/content/13/6/32.short
4100  - http://mdc.sagepub.com/content/13/6/32.full
AB  - Four to six cycles of platinum-based doublet chemotherapy remains the standard treatment protocol for most patients with advanced non-small cell lung cancer (NSCLC). Longer treatment does not appear to increase overall or progression-free survival and may lead to toxicity issues and reduced quality of life. This article discusses the current state of knowledge concerning treatment for NSCLC patients without a targetable (driver) mutation, the impact of oncogenic drivers on treatment of NSCLC, as well as the use of maintenance therapy for patients with cancer as a way to delay disease progression and improve survival.